Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis
Authors:
- 6 April 2020
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (9) , E497-E499
Abstract
No abstract availableKeywords
Funding Information
- Dermatology Foundation
This publication has 7 references indexed in Scilit:
- Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosisJournal of the European Academy of Dermatology and Venereology, 2020
- The IL-17 Family of Cytokines in Health and DiseaseImmunity, 2019
- WORSENING OF PULMONARY SARCOIDOSIS INDUCED BY IXEKIZUMAB: A RARE PARADOXChest, 2018
- Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) programJournal of the American Academy of Dermatology, 2018
- Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's diseaseRMD Open, 2015
- ApoE-Deficient Mice on Cholate-Containing High-Fat Diet Reveal a Pathology Similar to Lung SarcoidosisThe American Journal of Pathology, 2010
- A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nature Immunology, 2005